Emergent BioSolutions Appoints Barry Labinger As Executive Vice President Of The Company And President Of Its Biosciences Division

Emergent BioSolutions Inc. (NYSE:EBS) announced today that Barry Labinger has been named Executive Vice President and President, Biosciences Division, reporting directly to Daniel J. Abdun-Nabi, Emergent’s President and Chief Executive Officer. Mr. Labinger will be responsible for the strategic direction and management of the company’s biosciences division, including the development, manufacturing, and commercialization of biosciences product candidates; the advancement of partnering initiatives around Emergent’s biosciences programs and platform technologies MVAtor™ (modified vaccinia Ankara) and ADAPTIR™ (Modular Protein Technology); and the integration of future product acquisitions into the division.

“Barry brings to Emergent over two decades of extensive biopharmaceutical experience that encompasses general management, commercialization, and business development – core competencies that are integral to achieving the goals we have set in our growth plan,” said Daniel J. Abdun-Nabi, Emergent’s President and Chief Executive Officer. “As we look to expand our portfolio with specialized products that address the needs of hospitals and healthcare providers, Barry’s expertise will help greatly in establishing Emergent in the commercial marketplace.”

Mr. Labinger served as executive vice president and chief commercial officer at Human Genome Sciences, Inc. from 2005 to 2012. He has held a number of executive positions, including global head of 3M Pharmaceuticals from 2002 to 2005, and senior vice president and general manager commercial operations, and vice president, Enbrel marketing, at Immunex Corp. from 2000 to 2002. Mr. Labinger has held a number of leadership positions in pharmaceutical marketing at Bristol-Myers Squibb from 1997 to 2000 and Abbott Laboratories from 1990 to 1997. Mr. Labinger received his M.B.A. in Marketing, Finance and Management Policy and B.A. in Economics from Northwestern University.

About Emergent BioSolutions

Emergent BioSolutions is a specialty pharmaceutical company seeking to protect and enhance life by offering specialized products to healthcare providers and governments to address medical needs and emerging health threats. Additional information may be found at www.emergentbiosolutions.com. Follow us on twitter: @emergentbiosolu.

If you liked this article you might like

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Emergent BioSolutions (EBS) Highlighted As Weak On High Volume

New Lifetime High For Emergent BioSolutions (EBS)

New Lifetime High Reached By Emergent BioSolutions (EBS)

New Lifetime High Reached: Emergent BioSolutions (EBS)